“…In addition, curcumin inhibited NF-κB -induced production of CXCL1 and CXCL2 in breast cancer cells [ 72 ]. Curcumin can abrogate NF-κB pathway in multiple cancer cells [ 73 ], including breast cancer [ 74 , 75 , 76 , 77 , 78 , 79 , 80 , 81 ], colorectal cancer [ 82 , 83 ], human oral squamous carcinoma [ 84 ], human bladder cancer [ 85 , 86 ], cutaneous T-cell lymphoma [ 87 , 88 ], pancreatic cancer [ 89 ], head and neck squamous cell carcinoma [ 90 , 91 ], adenoid cystic carcinoma [ 92 ], glioblastoma [ 93 , 94 ], human tongue squamous cell carcinoma [ 95 ], human biliary cancer [ 96 ], medulloblastoma [ 97 ], gastric cancer [ 98 ], lymphoma [ 99 , 100 ], Myeloid-derived suppressor cells [ 101 ], ovarian cancer [ 102 ], T-cell and NFAT activation [ 103 ], rhabdomyosarcoma [ 104 , 105 ], esophageal adenocarcinoma [ 106 , 107 ], esophageal squamous cell carcinoma [ 108 , 109 ], human epidermoid carcinoma [ 110 ], prostate cancer [ 111 , 112 , 113 ], non-Hodgkin’s lymphoma [ 114 ], Hodgkin’s lymphoma [ …”